Form 4: Dyne Therapeutics Director Reports Stock Sales

Director Jason P. Rhodes sold shares of Dyne Therapeutics, Inc. common stock via a pre-arranged Rule 10b5-1 trading plan.

Summary

• Reporting person Jason P. Rhodes sold a total of 113,506 shares of Dyne Therapeutics common stock between May 4, 2026, and May 6, 2026.
• The sales were executed at weighted average prices ranging from $18.00 to $18.18 per share.
• Transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026.
• The shares sold were held indirectly through various Atlas Venture investment funds.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were conducted through a pre-planned, automated trading program rather than discretionary market timing.

Positives

• Sales were executed under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell stock without triggering concerns regarding non-public information.

Negatives

• The filing reflects a reduction in the indirect beneficial ownership stake held by entities associated with the director.

Risks

• Continued divestment by major institutional stakeholders or affiliated directors may influence market sentiment regarding the stock's valuation.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is common in the biotechnology sector as venture capital firms periodically rebalance portfolios or distribute assets to limited partners.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to ensure compliance with SEC regulations while liquidating equity positions.

Related Party Transactions

• The reporting person is a member of the general partner entities for several Atlas Venture funds that hold the shares.

Stakeholder Impact

• Shareholders should note the reduction in indirect holdings by the director's affiliated funds, though the systematic nature of the sales suggests portfolio management rather than a change in company outlook.

Next Steps

• Continued monitoring of future Form 4 filings to track further divestment or acquisition activity by the reporting person.

Key Dates

Keywords

Dyne Therapeutics, DYN, Insider Trading, Form 4, Biotech, Atlas Venture